A Phase I , Single Arm, Dose Escalation Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
Latest Information Update: 13 Dec 2021
At a glance
- Drugs Docetaxel (Primary) ; Tunlametinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Kechow Pharma
- 29 Nov 2021 Status changed from not yet recruiting to discontinued.
- 15 Dec 2020 Planned End Date changed from 1 Aug 2021 to 1 Dec 2022.
- 15 Dec 2020 Planned primary completion date changed from 1 Aug 2020 to 1 Dec 2022.